Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955994 · ClinicalTrials.gov registry record · Phase 2
Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00955994: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00955994 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00955994, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The treatment of acute pain in patients with irritable bowel symptoms is suboptimal. This is a placebo controlled study of the on demand treatment of pain experienced over a 4 week period in patients with irritable bowel syndrome. Patients will record the severity of pain when they take the study medication and two hours later.
Interventions
- DRUG asimadoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955994
The ClinicalTrials.gov registry entry for NCT00955994 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which asimadoline is the first listed.
NCT00955994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955994 about?
NCT00955994 is a clinical study titled "Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome". The treatment of acute pain in patients with irritable bowel symptoms is suboptimal. This is a placebo controlled study of the on demand treatment of pain experienced over a 4 week period in patients with irritable bowel syndrome. Patients will record the severity of pain when they take the study me...
What is the current status of trial NCT00955994?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2005-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00955994?
The interventions under investigation include: asimadoline (DRUG).
Who is sponsoring clinical trial NCT00955994?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.